Evidence map›Paper›PMID 38200223›Full record

ArticleNPJ precision oncology2024

Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics.

Alberto Valdeolivas, Bettina Amberg, Nicolas Giroud, Marion Richardson, Eric J C Gálvez, Solveig Badillo, Alice Julien-Laferrière, Demeter Túrós, Lena Voith von Voithenberg, Isabelle Wells and 13 more

Open access · goldAbstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. PRDM Proteins Orchestrate Colorectal Cancer Tumorigenesis.International journal of molecular sciences · 2026
    Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 2 countries.

Alberto ValdeolivasRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. alberto.valdeolivas_urbelz@roche.com.ORCID http://orcid.org/0000-0001-5482-9023
Bettina AmbergRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4526-3897
Nicolas GiroudRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Marion RichardsonRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Eric J C GálvezRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Solveig BadilloRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Alice Julien-LaferrièreRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Demeter TúrósInstitute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Lena Voith von VoithenbergRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Isabelle WellsRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Benedek PestiRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9055-6699
Amy A LoGenentech, Inc, San Francisco, CA, USA.
Emilio YángüezRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0003-4271-2690
Meghna Das ThakurGenentech, Inc, San Francisco, CA, USA.
Michael BscheiderRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Marc SultanRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Nadine KumpesaRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Björn JacobsenRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Tobias BergauerRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Julio Saez-RodriguezFaculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8552-8976
Sven RottenbergInstitute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0003-2044-9844
Petra C SchwalieRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Kerstin HahnRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. kerstin.hahn@roche.com.ORCID http://orcid.org/0000-0003-3602-4234
Roche (Switzerland) · CHUniversity of Bern · CHHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consensus molecular subtypes (CMS) of colorectal cancer (CRC) is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signals, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our study illustrates the potential of ST to resolve CRC molecular heterogeneity and thereby help advance personalized therapy.

Identifiers

PMID38200223
PMCPMC10781769
OpenAlexW4390691980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.